Obeticholic acid

From Ganfyd

Jump to: navigation, search
Obeticholic acid in primary biliary cholangitis shows superiority in reducing indirect surrogates for mortality and need for liver transplantation[1]. It also is in development in nonalcoholic steatohepatitis (NASH)[2]. It appears in animal models to modulate fibrosis induced by inflammation in a wide variety of systematic disease by Farnesoid X receptor (FXR) activation and accordingly could rapidly become important in clinical practice[3].

References

Personal tools